Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 51

DEA Clinical Trials THC Research and Development 51

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

CannaMD

NOVEMBER 20, 2020

Making matters worse, there’s only one farm in the entire country with DEA approval to cultivate marijuana for research purposes. A study by the American Medical Association found that 13% of workers experience a loss in productive time due to common pain conditions over a 2-week period. Marijuana in the Workplace. More Cannabis.

Therapy 104

Therapy Treatment DEA CBD 104

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. CBD Scheduling Rule Change. But the government is clear. What can CBD do?

CBD 105

CBD DEA Research and Development Hemp 105

Veriheal

DECEMBER 28, 2021

D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted. Many of these medical conditions are featured on the list of qualifying criteria for medical cannabis programs in the 37 U.S.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

MedicalJane

JUNE 29, 2018

Although this is exciting for many advocates of the plant, many patients that are suffering from ailing health conditions are left wondering what this means for them, and how exactly all of these changes will impact their healthcare options. Do you qualify for medical cannabis? There is no universal handbook for a medical cannabis program.

Patients 83

Patients Legalization Conditions Treatment 83

The Blunt Truth

MARCH 10, 2020

The latter requires extensive vetting , including analyses of the underlying target condition and other related available treatments, conducting a cost benefit analysis from clinical data, as well as strategizing on how drug risks may be identified and mitigated. CBD Class Action Litigation.

CBD 99

CBD Topical Agriculture Hemp 99

The Cannigma

MAY 6, 2021

Technically speaking, it’s not produced by the plant, but is rather a degradation product of delta-9-THC, often as a result of aging and storage conditions. Delta-8-THC, like many other cannabinoids, was first identified by Roger Adams in the 1940s, and further synthesized by Raphael Mechoulam in the 1960s.

THC 145

THC Cannabinoids Concentrates Hemp 145

Veriheal

APRIL 11, 2022

Drug Enforcement Agency (DEA). According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. Groff confirmed that it had completed its first batch of medicinal-grade cannabis for research purposes on Feb.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

The Joint Blog

JUNE 4, 2021

Believe it or not, you actually need a license to do meaningful research on marijuana due to the fact that the United States Drug Enforcement Agency (DEA) has limited its access. The DEA feels that marijuana, being a schedule I drug, could be misused like other drugs within that category and could be dangerous. Cancer pain.

Conditions 32

Conditions Chronic Pain Marijuana Research and Development 32

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Drug Enforcement Agency (“DEA”). Id ; 21 CFR 312.1-10; 10; 312.80-88; 88; 312.300 et seq.

Law 81

Law Therapy Clinical Trials Decriminalization 81

Veriheal

MAY 13, 2022

According to the Drug Enforcement Administration (DEA) website , magic mushrooms are recognizable by their slender stems, which are “topped by caps with dark gills on the underside.” At the same time, psilocybin has been found to potentially improve some mental conditions, such as depression.

Research and Development 98

Research and Development Legalization Consumption Microdosing 98

Cannabis Law Report

JUNE 20, 2019

Although the use of cannabis is legal for medical and/or recreational use in many states, the United States Drug Enforcement Agency (DEA) continues to classify the whole cannabis plant as a Schedule I controlled substance, which is defined as “drugs with no currently accepted medical use and a high potential for abuse.” Source: [link].

THC 74

THC CBD Oil DEA 74

The Cannigma

MAY 1, 2023

According to the DEA, “substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.” Brain plasticity is basically the brain’s ability to adapt to stress, trauma, and injury. 9 How is ketamine commonly used?

Blood Pressure 98

Blood Pressure Chronic Pain Research and Development Clinical Trials 98

Cannabis Law Report

AUGUST 23, 2021

FDA has not reviewed the manufacturing process of these unapproved CBD-containing drug products, so the manufacturing conditions of, or contaminant levels in, these products is unknown. Practicing veterinarians face a barrage of questions from pet owners about the use of CBD animal products for conditions ranging from arthritis to anxiety.

Pets 105

Pets Hemp CBD Food 105

SpeedWeed

MARCH 28, 2021

Phase 2 trials usually involve hundreds of patients and test whether the drug works in people who have a certain disease or condition. The good news is that all groups, including the placebo, showed improvement in PTSD symptoms during the treatment, with the THC group showing the largest response. View original article.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. These designations indicate that psychedelics may represent substantial improvements over existing treatments for mental health conditions.

Law 81

Law Research and Development Therapy DEA 81

United Patients Group

APRIL 3, 2023

Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019. The doctor who writes the prescription must be licensed and has to write it for a specific patient, as opposed to prescribing general instructions for treatment.

DEA 52

DEA Patients Conditions Cannabis 52

MedicalJane

OCTOBER 5, 2017

Standard treatment for severe cramps and pain. An over-the-counter medication like Midol, or an NSAID like ibuprofen, are conventional treatments that are commonly used to treat mild symptoms of menstrual cramps. So where are women to turn for natural, alternative forms of treatment that may provide relief? The Pagano study.

Marijuana 65

Marijuana Treatment Extraction Medicine 65

Veriheal

DECEMBER 27, 2022

Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .

Research and Development 102

Research and Development Therapy Consumption DEA 102

Cannabis Law Report

AUGUST 18, 2022

Smith , a partner with the firm and co-leader of the firm’s Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments. Tweet this. However, change appears imminent.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

NOVEMBER 20, 2021

Drug Enforcement Administration (DEA), the Alabama Prescription Drug Monitoring Program maintained by Alabama Department of Public Health, and the Alabama Medical Cannabis Patient Registry System maintained by the Alabama Medical Cannabis Commission. Obtaining this permit requires the physician to: complete an application. 31 each year.

Patients 52

Patients DEA Dispensary Conditions 52

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. Conclusion. Source: [link].

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

MARCH 21, 2019

Although the DEA refuses to remove marijuana from the schedule 1 list, the Farm Bill is considered to be the most important victory in the history of U.S. If you reside in any of the following 15 states, there are laws stating certain conditions must be met in order to legally obtain CBD.

State Laws 55

State Laws Law CBD Legalization 55

CannaMD

MAY 6, 2020

In practice, the chances of feds or the DEA sitting at the border waiting to catch someone – that’s just not happening. If a patient from out of state is in Maryland for medical treatment, they can register to receive medical marijuana, but the state does not recognize out-of-state medical marijuana cards. Possession Limit: 2.5

Hash 105

Hash Legalization Marijuana Concentrates 105

The Blunt Truth

OCTOBER 24, 2019

Speaking of Connecticut, the state just added several conditions to the list of permissible uses of medical marijuana. Tourette syndrome and intractable neuropathic pain are now eligible for treatment with medical cannabis. Maybe Colorado should convene something similar to get South Dakota on board with hemp?

Hemp 58

Hemp DEA CBD Topical 58

SpeedWeed

AUGUST 11, 2021

Suicide among veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for pain, depression, and PTSD,” said Sisley in a press statement. This trial will be the second of its kind to be conducted so far, and one that is an FDA- and DEA-regulated double-blind, placebo-controlled study.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

JULY 27, 2022

Each jurisdiction has its own criteria regarding what conditions cannabis can be prescribed for, in what amounts, and the process for issuing medical marijuana licenses. For this reason, the FDA and DEA have concluded that marijuana has no federally approved medical use in the U.S. By Raymond Lahoud. July 27, 2022.

Marijuana 52

Marijuana DEA State Laws Policy 52

Cannabis Law Report

MAY 17, 2019

Seq (1970) and Drug Enforcement Administration’s (“DEA”) clutches, 2019 hemp production and sales exploded. A wildly popular nutritional supplement and food additive, oil based hemp derived products like CBD racked up $1.1 Farm Bill’s Impact and Rise of the FDA. Beyond removing plant cannabis sativa L. Budgeted at $6.1

Food 10

Food DEA Hemp CBD 10

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

PrestoDoctor

JANUARY 14, 2020

They are responsible for giving you information about the treatment and proper use. The physician will conduct an evaluation to determine if your medical condition can improve with marijuana use. The physician may review a list of qualifying conditions. Oklahoma does not have a specific list of conditions to get an MMJ.

Marijuana 52

Marijuana Patients Conditions Programs 52

PrestoDoctor

JANUARY 14, 2020

They are responsible for giving you information about the treatment and proper use. The physician will conduct an evaluation to determine if your medical condition can improve with marijuana use. The physician may review a list of qualifying conditions. Oklahoma does not have a specific list of conditions to get an MMJ.

Marijuana 52

Marijuana Patients Conditions Programs 52

Cannabis Law Report

MAY 31, 2022

Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression. The Drug Enforcement Agency (DEA) currently has guidance published for those interested in petitioning for a religious exemption to the CSA. On March 5, 2019, the U.S.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

APRIL 14, 2022

Local governments may also impose zoning conditions on cannabis facilities, including but not limited to buffer zones, density conditions, hours of operation, odor control requirements, necessary operating permits, and storefront characteristics. pursuant to Drug Enforcement Agency (DEA) or state-level programs).

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

JULY 30, 2019

Patients carefully consider a choice of cannabis physician based on their personal past health, their qualifying condition, and their current health needs: essentially, patients decide which physician can serve that patient’s needs by adding cannabis as a therapeutic medication. . Federal Register. .

Marijuana 45

Marijuana Patients Research and Development Programs 45

Cannabis Law Report

APRIL 13, 2022

Best-in-class service offering with clinics providing a wide range of traditional, innovative and psychedelic mental health treatments that can be appropriately matched to each client’s needs. Completion of the Transaction is subject to a number of conditions including the receipt of regulatory, TSX and CSE approvals.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

SpeedWeed

MARCH 5, 2021

One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances.

Business 52

Business Policy Clinical Trials Research and Development 52